Efficacy of Curosurf in a rat model of acute respiratory distress syndrome

European Respiratory Journal

Volumn 12, Issue 3, 1998, Pages 533-539

  Van Helden, H P M ^a   Kuijpers, W C ^a   Langerwerf, P E J ^a   Langen, R C J ^a   Haagsman, H P ^b   Bruijnzeel, P L B ^a  

^a TNO   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Acute respiratory distress syndrome; Animal model; Curosurf; Lung surfactant

Indexed keywords

LIPOPOLYSACCHARIDE; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATHING RATE; CONTROLLED STUDY; CYTOCHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFICACY; INTRATRACHEAL DRUG ADMINISTRATION; LUNG LAVAGE; LUNG WEIGHT; MALE; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RAT; RESPIRATORY DISTRESS; SURVIVAL RATE;

ANALYSIS OF VARIANCE; ANIMALS; BIOLOGICAL PRODUCTS; BRONCHIAL PROVOCATION TESTS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, SPINAL; LIPOPOLYSACCHARIDES; LUNG; MALE; ORGAN SIZE; PHOSPHOLIPIDS; PULMONARY SURFACTANTS; RATS; RATS, WISTAR; REFERENCE VALUES; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY FUNCTION TESTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031664145     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.12030533     Document Type: Article

References (27)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967; 2: 319-323.
2. Milberg JA, Davis DR, Steinberg KP, Hudson LD. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995; 273 (4): 306-309.
3. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med 1996; 334: 1417-1421.
4. Lachmann B, Danzmann E. Acute respiratory distress syndrome. In: Robertson B, Van Golden LMG, Batenburg JJ, eds. Pulmonary Surfactant. Amsterdam, Elsevier, 1984; pp. 505-548.
5. Gregory TJ, Longmore WJ, Moxley MA. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88: 1976-1981.
6. Lachmann B. The role of pulmonary surfactant in the pathogenesis of ARDS. In: Vincent JL, ed. Update in Intensive Care and Emergency Medicine. Berlin, Heidelberg, New York, Springer, 1987; pp. 123-134.
7. Richman PS, Spragg RG, Robertson B, Merritt TA, Curstedt T. The adult respiratory distress syndrome: first trials with surfactant replacement. Eur Respir J 1989; 2: 109-111.
8. Nosaka S, Sakai T, Yonekura M, Yoshikawa K. Surfactant for adults with respiratory failure. Lancet 1990; 1: 947-948.
9. Gommers D, Lachmann B. Surfactant therapy: does it have a role in adults? Clin Int Care 1993; 4: 284-295.
10. Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis 1993; 147: 218-233.
11. Lachmann B, Van Daal GJ. Adult respiratory distress syndrome: animal models. In: Robertson B, Van Golden LMG, Batenburg JJ, eds. Pulmonary Surfactant. Amsterdam, Elsevier, 1992: pp. 635-663.
12. Spragg RG. Clinical results after natural and artificial exogenous surfactant therapy. Appl Cardiopulm Pathophysiol 1995; 5: 116.
13. Gadek JE, Gregory TJ, Hyers TM, Longmore WJ, Spragg R, Steinberg KP. Patterns of improvement of gas exchange during treatment of patients with the adult respiratory distress syndrome with a bovine derived surfactant. Appl Cardiopulm Pathophysiol 1995; 5: 36.
14. Gregory TJ, Steinberg KP, Spragg R, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155 (4): 1309-1315.
15. Walmrath D, Gunther A, Ghofrani HA, et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 1996; 154; 57-62.
16. Van Helden HPM, Kuijpers WC, Steenvoorden D, et al. Intratracheal aerosolization of endotoxin (LPS) in the rat: a comprehensive animal model to study Adult (Acute) Respiratory Distress Syndrome (ARDS). Exp Lung Research 1991; 23: 291-315.
17. Bradford MM. A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976; 72: 248-254.
18. Lachmann B, Gommers D, Eijking EP. Exogenous surfactant therapy in adults. Atemw Lungenkrkh 1993; 12: S581-S591.
19. Kobayashi T, Tashiro K, Li WZ, Matsumoto Y, Yamada K. Experimental experiences with exogenous surfactant in animals with adult respiratory distress syndrome (ARDS). Appl Cardiopulm Pathophysiol 1993; 5: 71-72.
20. Jobe AH, Ueda T, Henry M, Ikegami M. Clearance of the major surfactant components from rabbit lungs. Appl Cardiopulm Pathophysiol 1995; 5: 65-66.
21. Cockshutt AM, Weitz J, Possmayer F. Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 1990; 29: 8424-8429.
22. Yukitake K, Brown CL, Schlueter MA, Clements JA, Hawgood S. Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo. Pediatr Res 1995 ; 37: 21-25.
23. Putman E, Creuwels LAJM, Van Golde LMG, Haagsman HP. Surface properties, morphology, and protein composition of pulmonary surfactant subtypes. Biochem J 1996; 320: 599-605.
24. Malloy J, McCaig L, Veldhuizen R, et al. Alterations of the endogenous surfactant system in septic adult rats. Am J Respir Crit Care Med 1997; 156: 617-623.
25. Clements JA. Function of the alveolar lining. Am Rev Respir Dis 1977; 115: 67-71.
26. McIntosh JC, Wright JR. SP-A decreases TNFα production by LPS-activated macrophages. Appl Cardiopulm Pathophysiol 1995; 5: 80-81.
27. Whitsett JA, Clark JC, Wisp JR, Pryhuber GS. Effects of TNF-α and phorbol ester on human surfactant protein and MnSOD gene transcription in vitro. Am J Physiol 1992; 262: L688-L693.